var data={"title":"Group B streptococcal infection in neonates and young infants","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Group B streptococcal infection in neonates and young infants</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/contributors\" class=\"contributor contributor_credentials\">Karen M Puopolo, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/contributors\" class=\"contributor contributor_credentials\">Carol J Baker, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/contributors\" class=\"contributor contributor_credentials\">Leonard E Weisman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/contributors\" class=\"contributor contributor_credentials\">Carrie Armsby, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 02, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Group B <em>Streptococcus</em> (GBS or <em>Streptococcus agalactiae</em>) is gram-positive diplococcus that is a common colonizer of the gastrointestinal and genital tracts. GBS colonization in pregnant women is generally asymptomatic. However, maternal colonization is the primary risk factor for GBS infection in neonates and young infants [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>GBS infection in neonates and young infants will be reviewed here. The microbiology of GBS infections, the prevention of GBS infection in neonates, the management of infants whose mother received GBS chemoprophylaxis, and the diagnosis and management of neonatal sepsis broadly are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=group-b-streptococcus-virulence-factors-and-pathogenic-mechanisms\" class=\"medical medical_review\">&quot;Group B streptococcus: Virulence factors and pathogenic mechanisms&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis\" class=\"medical medical_review\">&quot;Management of the infant whose mother has received group B streptococcal chemoprophylaxis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Group B streptococcal (GBS) infection in neonates and young infants is classified by age at onset [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Early-onset GBS</strong> &mdash; Early-onset GBS generally presents at or within 24 hours of birth [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/4\" class=\"abstract_t\">4</a>] but can occur through day 6 after birth.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Late-onset GBS</strong> &mdash; Late-onset GBS usually occurs at four to five weeks of age (range 7 to 89 days).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Late, late-onset GBS</strong> &mdash; Late, late-onset GBS (also called very-late-onset GBS or GBS beyond early infancy) occurs in infants older than three months of age. Late, late-onset GBS infections are most common in infants who are born before 28 weeks' gestation or in children with a history of immunodeficiency [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neonatal GBS infection is acquired in utero through clinically apparent or &quot;silent&quot; intra-amniotic infection, rupture or membranes, or during passage through the vagina [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/7\" class=\"abstract_t\">7</a>]. Evidence suggests that vaginal colonization with a high inoculum (&gt;10&#8309; <span class=\"nowrap\">cfu/mL)</span> of GBS during pregnancy increases the risk of vertical transmission [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/8,9\" class=\"abstract_t\">8,9</a>] and early-onset disease in neonates. After discharge from the hospital, young infants also can acquire GBS from colonized household contacts and go on to develop late-onset bacteremia, meningitis, or other focal infections.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Incidence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The United States Centers for Disease Control and Prevention began active surveillance for GBS in 1990 [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/10\" class=\"abstract_t\">10</a>]. Since that time, the following trends have been noted:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Early-onset disease</strong> &ndash; The incidence of early-onset GBS disease declined from 1.8 cases per 1000 live births in 1990 to 0.23 cases per 1000 live births in 2015 (<a href=\"image.htm?imageKey=PEDS%2F54049\" class=\"graphic graphic_figure graphicRef54049 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/10-14\" class=\"abstract_t\">10-14</a>]. There is an ongoing ethnic disparity, with black neonates at significantly greater risk of infection than white neonates (0.57 versus 0.15 cases per 1000 live births, respectively) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,14\" class=\"abstract_t\">13,14</a>].</p><p/><p class=\"bulletIndent1\">The overall decline in early-onset GBS disease has been attributed to universal screening of pregnant women for GBS colonization and the widespread use of intrapartum antibiotic prophylaxis (IAP) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/2,15-17\" class=\"abstract_t\">2,15-17</a>]. Despite implementation of prevention policies, early-onset neonatal GBS disease continues to occur and has plateaued since the mid-2000s [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/18-22\" class=\"abstract_t\">18-22</a>]. Prior to routine maternal screening and use of IAP, the majority of early-onset GBS disease occurred in term neonates; however, in the contemporary era, approximately 50 percent of cases occur in preterm neonates among whom the risk of mortality is substantially higher [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,19-21\" class=\"abstract_t\">13,19-21</a>]. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Late-onset disease</strong> &ndash; The incidence of late-onset GBS disease in the United States has remained stable since 1990 at approximately 0.3 to 0.4 per 1000 live births (<a href=\"image.htm?imageKey=PEDS%2F54049\" class=\"graphic graphic_figure graphicRef54049 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/14\" class=\"abstract_t\">14</a>]. Late-onset disease is not prevented by maternal intrapartum chemoprophylaxis [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/10-13,23-26\" class=\"abstract_t\">10-13,23-26</a>]. Slightly more than one-half of infants with late-onset disease are born before 37 weeks' gestation, with a median gestational age of 30 weeks [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,25\" class=\"abstract_t\">13,25</a>]. As with early-onset GBS disease, there is an ongoing racial disparity, with black infants at greater risk of infection than white infants (0.68 versus 0.25 cases per 1000 live births, respectively) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary risk factor for early-onset GBS infection is maternal GBS genitourinary or gastrointestinal colonization [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/1,16\" class=\"abstract_t\">1,16</a>]. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention#H2\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;, section on 'Identification of colonized gravidas'</a>.)</p><p>The rate of transmission from colonized mothers to infants without intrapartum antibiotic prophylaxis is approximately 50 percent [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/1,27\" class=\"abstract_t\">1,27</a>]. However, only 1 to 2 percent of all infants born to colonized pregnant women develop early-onset GBS disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/1,4\" class=\"abstract_t\">1,4</a>]. Up to 50 percent of late-onset disease was thought to be attributable to vertical transmission before the widespread introduction of maternal IAP for GBS carriers [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/9\" class=\"abstract_t\">9</a>]. IAP has had no impact on the incidence of late-onset disease, which is not surprising given that IAP eliminates or diminishes neonatal exposure only during labor and delivery; women given IAP continued to be colonized postpartum. This suggests that the GBS exposures of infants with late-onset disease occur in the home, from colonized parents or siblings, or in the community, and that these exposures are important in the pathogenesis of late-onset disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/28-30\" class=\"abstract_t\">28-30</a>].</p><p>Several maternal obstetrical factors have been associated with increased risk of developing early-onset GBS disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/2,15,31-33\" class=\"abstract_t\">2,15,31-33</a>]. These clinical risk factors include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Delivery at &lt;37 weeks of gestation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Premature rupture of membranes at any gestation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rupture of membranes for &ge;18 hours before delivery</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chorioamnionitis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>GBS bacteriuria during the current pregnancy (&gt;10<sup>4</sup> <span class=\"nowrap\">cfu/mL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Temperature &ge;38&deg;C, or 100.4&deg;F, during labor</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior delivery of an infant with GBS disease</p><p/><p>Multiple-gestation pregnancy has been associated with increased risk of GBS disease (early- or late-onset) in some [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/34,35\" class=\"abstract_t\">34,35</a>], but not all, studies [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p>Bacterial and immunologic risk factors include [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/8,9,38-42\" class=\"abstract_t\">8,9,38-42</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>GBS strain with enhanced virulence</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heavy maternal colonization (vaginal inoculum &gt;10<sup>5</sup> <span class=\"nowrap\">cfu/mL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Deficient maternal GBS capsular type-specific immunoglobulin G at term delivery</p><p/><p>These risk factors have been used to develop guidelines for screening pregnant women for GBS and administration of IAP to prevent neonatal GBS infection. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Serotype distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GBS serotype corresponds to the capsular polysaccharide. Surface proteins, including the C proteins, also are used for the classification of GBS strains. There are 10 GBS serotypes: Ia, Ib, and II through IX [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3,43\" class=\"abstract_t\">3,43</a>].</p><p>Serotypes Ia, Ib, II, III, and V account for more than 95 percent of early-onset cases in the United States and more than 90 percent of late-onset cases [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13\" class=\"abstract_t\">13</a>]. Serotype III has a propensity to cause meningitis and is responsible for a high proportion of late-onset infections [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,44\" class=\"abstract_t\">13,44</a>].</p><p>The distribution of serotypes and surface proteins among GBS isolates has important implications for the development of vaccines to prevent GBS disease. (See <a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">&quot;Vaccines for the prevention of group B streptococcal disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Early-onset disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early-onset group B streptococcal (GBS) infection most commonly manifests as generalized sepsis, pneumonia, or meningitis [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13\" class=\"abstract_t\">13</a>]. In &gt;90 percent of cases, clinical signs are apparent in the first 24 hours after birth.</p><p>Infants whose mothers receive intrapartum antibiotic prophylaxis (IAP) are less likely to have sepsis, need assisted ventilation, or have documented GBS bacteremia [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/45\" class=\"abstract_t\">45</a>]. Exposure to IAP does not appear to alter the clinical spectrum of disease or the time of onset of clinical signs of infection [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27,46\" class=\"abstract_t\">27,46</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Sepsis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sepsis without a focus of infection occurs in 80 to 85 percent of cases of early-onset GBS disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13\" class=\"abstract_t\">13</a>]. Signs of sepsis are nonspecific and include irritability, lethargy, respiratory symptoms (eg, tachypnea, grunting, hypoxia), temperature instability, poor perfusion, and hypotension (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 1</a>). Many infants presenting at &lt;24 hours after birth do not have fever, although fever can occur in term infants on the second or third day after birth. Sepsis syndromes range from nonspecific signs to profound septic shock. Early-onset disease can be associated with persistent pulmonary hypertension of the newborn (PPHN). (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;</a> and <a href=\"topic.htm?path=persistent-pulmonary-hypertension-of-the-newborn\" class=\"medical medical_review\">&quot;Persistent pulmonary hypertension of the newborn&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pneumonia occurs in approximately 10 percent of cases of early-onset disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13\" class=\"abstract_t\">13</a>]. Signs of pneumonia include tachypnea, grunting, hypoxia, and increased work of breathing. GBS pneumonia also may be associated with PPHN in term infants. (See <a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">&quot;Neonatal pneumonia&quot;</a> and <a href=\"topic.htm?path=persistent-pulmonary-hypertension-of-the-newborn\" class=\"medical medical_review\">&quot;Persistent pulmonary hypertension of the newborn&quot;</a>.)</p><p>Radiographic findings of GBS pneumonia include a diffuse alveolar pattern that can be difficult to distinguish from hyaline membrane disease or transient tachypnea of the newborn [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/47\" class=\"abstract_t\">47</a>]. Pleural effusions are more common in GBS pneumonia than in hyaline membrane disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/31,48,49\" class=\"abstract_t\">31,48,49</a>]. (See <a href=\"topic.htm?path=pathophysiology-clinical-manifestations-and-diagnosis-of-respiratory-distress-syndrome-in-the-newborn\" class=\"medical medical_review\">&quot;Pathophysiology, clinical manifestations, and diagnosis of respiratory distress syndrome in the newborn&quot;</a> and <a href=\"topic.htm?path=prevention-and-treatment-of-respiratory-distress-syndrome-in-preterm-infants\" class=\"medical medical_review\">&quot;Prevention and treatment of respiratory distress syndrome in preterm infants&quot;</a> and <a href=\"topic.htm?path=transient-tachypnea-of-the-newborn\" class=\"medical medical_review\">&quot;Transient tachypnea of the newborn&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Meningitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>GBS meningitis occurs in 7 percent of cases of early-onset disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13\" class=\"abstract_t\">13</a>]. Early-onset GBS meningitis uncommonly presents with signs of central nervous system (CNS) inflammation; respiratory abnormalities (eg, tachypnea, grunting, apnea) are the most frequent presentation [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/50,51\" class=\"abstract_t\">50,51</a>]. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Clinical features and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Late-onset disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Late-onset GBS disease most often presents as bacteremia without a focus (approximately 65 percent of cases) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,52\" class=\"abstract_t\">13,52</a>]. However, meningitis (25 to 30 percent) and focal infections also occur [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/53\" class=\"abstract_t\">53</a>]. Compared with those with early-onset disease, infants with late-onset disease are less likely to manifest profound shock and, among those with meningitis, are more likely to have clinically apparent seizures [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Bacteremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants with late-onset infection commonly present with fever &ge;38&deg;C. These infants may have a history of a preceding or intercurrent upper respiratory infection. Other clinical findings can include irritability, lethargy, poor feeding, tachypnea, grunting, and occasionally apnea.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Meningitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Meningitis accounts for 25 to 30 percent of cases of late-onset GBS disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. The clinical presentation of neonatal meningitis typically is indistinguishable from that of neonatal sepsis without meningitis. The most commonly reported clinical signs are temperature instability, irritability or lethargy, and poor feeding or vomiting. The classic signs of meningitis (eg, bulging fontanel, nuchal rigidity, focal neurologic findings) are more common in late-onset than early-onset GBS meningitis [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/54\" class=\"abstract_t\">54</a>]. In 20 to 30 percent of late-onset cases, there are preceding signs of upper respiratory infection [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/1,50,55\" class=\"abstract_t\">1,50,55</a>]. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Clinical features and diagnosis&quot;, section on 'Clinical features'</a> and <a href=\"topic.htm?path=bacterial-meningitis-in-children-older-than-one-month-clinical-features-and-diagnosis#H5\" class=\"medical medical_review\">&quot;Bacterial meningitis in children older than one month: Clinical features and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Other focal infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Late-onset disease also can present as pneumonia, septic arthritis, osteomyelitis, cellulitis, and adenitis [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/53\" class=\"abstract_t\">53</a>]. Rare presentations of late-onset GBS disease include endocarditis, myocarditis, pericarditis, pyelonephritis, endophthalmitis, and brain abscess, among others [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Bone/joint</span> infection</strong> &ndash; Late-onset GBS infection manifests as septic arthritis and osteomyelitis in approximately 5 percent of cases [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. GBS septic arthritis generally has an acute presentation and involves the lower extremity; the mean age of onset is 20 days. GBS osteomyelitis typically has an insidious onset; the most frequent sites include the humerus, especially the right proximal humerus, femur, and tibia; the mean age of onset is 31 days. These manifestations of late-onset disease have decreased in frequency, most likely due to more prompt diagnosis and empiric treatment of GBS bacteremia without a focus.</p><p/><p class=\"bulletIndent1\">Decreased movement of the involved extremity and pain with manipulation are important clues to GBS bone and joint infection [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27,56\" class=\"abstract_t\">27,56</a>]. Fever is absent in the majority of patients. Concomitant bacteremia is present in more than one-half of cases [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/56\" class=\"abstract_t\">56</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cellulitis-adenitis</strong> &ndash; Late-onset GBS infection can manifest as cellulitis <span class=\"nowrap\">and/or</span> adenitis, most commonly involving the face or submandibular area, though other areas may be affected [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. Cellulitis-adenitis accounted for 4 percent of late-onset GBS infections in an 11-year series from one institution [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/57\" class=\"abstract_t\">57</a>]. Associated examination findings can include ipsilateral otitis media; infected or thyroglossal duct cyst also has been reported [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"bulletIndent1\">In a review of 32 cases of GBS cellulitis-adenitis, bacteremia was documented in 91 percent of cases [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/59\" class=\"abstract_t\">59</a>]. Among the 25 infants in whom cerebrospinal fluid (CSF) was obtained, six grew GBS from the CSF; three infants died: two had CNS involvement and one fulminant GBS septicemia. Lack of fever and well appearance at presentation did not predict subsequent clinical course.</p><p/><p class=\"bulletIndent1\">These observations suggest that lumbar puncture should be performed in young infants with cellulitis-adenitis and that empiric antibiotics should include coverage for GBS meningitis until CNS infection is excluded [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"#H21\" class=\"local\">'Evaluation'</a> below and <a href=\"#H28\" class=\"local\">'Empiric therapy'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Late, late-onset disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Late, late-onset GBS disease most commonly occurs in preterm infants born at &lt;28 weeks of gestation [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/5,27,52\" class=\"abstract_t\">5,27,52</a>]. It typically manifests as bacteremia without a focus, but focal sites of infection may be noted, including the CNS, soft tissues, bones and joints, and intravascular catheters [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/5,13,27\" class=\"abstract_t\">5,13,27</a>].</p><p>GBS infection after six months of age can be the first sign of immune deficiency, including HIV infection [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/5,60,61\" class=\"abstract_t\">5,60,61</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">EVALUATION</span></p><p class=\"headingAnchor\" id=\"H593758555\"><span class=\"h2\">Clinical suspicion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants with signs of sepsis require prompt evaluation and initiation of antibiotic therapy. Because the signs of sepsis in neonates and young infants are subtle and nonspecific (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 1</a>), newborn care providers use established risk factors for neonatal early-onset sepsis together with the newborn clinical condition to identify newborns at highest risk of infection. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H12\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Evaluation and initial management'</a>.)</p><p>For patients presenting within the first six days after birth (early-onset disease), it is crucial to review the pregnancy, labor, and delivery history to identify factors associated with increased risk of sepsis (eg, maternal intra-amniotic infection, inadequate maternal intrapartum antibiotic prophylaxis [IAP], preterm delivery, prolonged duration of rupture of membranes) (<a href=\"image.htm?imageKey=PEDS%2F56780\" class=\"graphic graphic_algorithm graphicRef56780 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/62\" class=\"abstract_t\">62</a>]. Validated risk assessment tools (eg, the <a href=\"https://neonatalsepsiscalculator.kaiserpermanente.org/&amp;token=onMkmNxqZshoDc22JN8OR+QKCg7t0pcaNNq2h8esYG515dR4JaAxDq9tt4oaRDV5Qc/bUukpm4cZ872Q8bCopQ==&amp;TOPIC_ID=5961\" target=\"_blank\" class=\"external\">early-onset sepsis calculator</a>) can help guide decisions regarding the extent of evaluation and the administration of empiric antibiotics [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/63\" class=\"abstract_t\">63</a>]. (See <a href=\"topic.htm?path=management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis#H481658626\" class=\"medical medical_review\">&quot;Management of the infant whose mother has received group B streptococcal chemoprophylaxis&quot;, section on 'Risk estimators'</a>.)</p><p>GBS status of the mother is also important to consider in infants presenting beyond six days of age (late-onset disease); however, factors such as maternal IAP and duration of rupture of membranes are not weighed in decision-making in late-onset disease. Maternal IAP does not decrease the risk of late-onset GBS disease. Decisions to evaluate and initiate empiric treatment for late-onset sepsis are based chiefly on clinical appearance and signs of illness. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H96559382\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Late-onset sepsis'</a> and <a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation#H3698483132\" class=\"medical medical_review\">&quot;Febrile infant (younger than 90 days of age): Outpatient evaluation&quot;, section on 'Evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Tests to perform in the index patient</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Evaluation for suspected GBS infection in the index patient includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count (CBC) with differential</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood culture</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest radiograph (if respiratory signs present)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lumbar puncture for cerebrospinal fluid (CSF) cell count, protein and glucose concentration, Gram stain and culture</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urine culture (if the infant is &gt;6 days of age) by sterile collection method (urinary catheter or suprapubic aspirate)</p><p/><p>The lumbar puncture should be performed before the institution of antibiotic therapy, unless the infant is clinically unstable, and in that circumstance the lumbar puncture can be deferred.</p><p>Interpretation of the CBC should consider the timing of the evaluation and the gestational age of the infant. (See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H686757573\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Complete blood count'</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation#H176900390\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)&quot;, section on 'Neutrophil counts'</a>.)</p><p>Additional studies may be necessary if osteoarticular infection is suspected. These include radiographs of the involved site, magnetic resonance imaging, bone biopsy, or joint aspiration with culture and susceptibility testing. (See <a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-evaluation-and-diagnosis#H18\" class=\"medical medical_review\">&quot;Hematogenous osteomyelitis in children: Evaluation and diagnosis&quot;, section on 'Diagnostic approach'</a> and <a href=\"topic.htm?path=bacterial-arthritis-clinical-features-and-diagnosis-in-infants-and-children#H8\" class=\"medical medical_review\">&quot;Bacterial arthritis: Clinical features and diagnosis in infants and children&quot;, section on 'Evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Evaluation of a twin sibling</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When a twin (or other infant product of a multiple-birth gestation) is diagnosed with GBS disease, the sibling of the index case should be observed carefully [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>]. If any signs of illness occur, he or she should be evaluated (as described for the index patient above) and treated empirically for GBS. Although the unaffected twin is likely to be colonized with GBS (given the common contacts), evidence is lacking that prophylactic antibiotic treatment decreases the risk of subsequent infection. (See <a href=\"#H22\" class=\"local\">'Tests to perform in the index patient'</a> above and <a href=\"#H28\" class=\"local\">'Empiric therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Isolation of GBS from a normally sterile body site (eg, blood, cerebrospinal fluid [CSF], pleural fluid, bone, joint) confirms the diagnosis of GBS infection. GBS antigen may be detected in CSF, which occasionally can assist in the diagnosis of infection [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>]. However, antigen testing of other body fluids is not recommended because of poor specificity.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antimicrobial therapy and supportive care combined with drainage of purulent collections as necessary are the cornerstones of treatment of GBS disease in neonates and young infants.</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive care for neonates and young infants with GBS infection may include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ventilatory support (including endotracheal intubation and mechanical ventilation) (see <a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">&quot;Mechanical ventilation in neonates&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prompt recognition and treatment of shock (see <a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock\" class=\"medical medical_review\">&quot;Etiology, clinical manifestations, evaluation, and management of neonatal shock&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Careful maintenance of fluid and electrolyte balance (see <a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">&quot;Fluid and electrolyte therapy in newborns&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of anemia (see <a href=\"topic.htm?path=anemia-of-prematurity\" class=\"medical medical_review\">&quot;Anemia of prematurity&quot;</a> and <a href=\"topic.htm?path=red-blood-cell-transfusions-in-the-newborn\" class=\"medical medical_review\">&quot;Red blood cell transfusions in the newborn&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of seizures seizure control (see <a href=\"topic.htm?path=treatment-of-neonatal-seizures\" class=\"medical medical_review\">&quot;Treatment of neonatal seizures&quot;</a>)</p><p/><p>Management in an intensive care unit is often required.</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h2\">Antimicrobial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antimicrobial therapy for neonates and infants has not been evaluated in randomized, controlled trials. Recommendations for treatment are based upon in vitro susceptibility testing and response to therapy in observational studies.</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h3\">Empiric therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial empiric antibiotic therapy of suspected sepsis includes broad coverage for organisms known to cause early- and late-onset disease in neonates and infants younger than three months of age (eg, GBS and other streptococci, gram-negative enteric organisms, and, rarely, <em>Listeria monocytogenes</em>) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. Appropriate regimens for empiric therapy vary depending upon the focus of infection and whether the infection is early onset or late onset (<a href=\"image.htm?imageKey=ID%2F66906\" class=\"graphic graphic_table graphicRef66906 \">table 2</a>). Local antibiotic resistance patterns should also be considered. (See <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H4\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Initial empiric therapy'</a>.)</p><p>In the era of GBS intrapartum antibiotic prophylaxis (IAP), with decreases in the incidence of early-onset GBS disease, up to 50 percent of early-onset sepsis is due to ampicillin-resistant gram-negative organisms [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/64,65\" class=\"abstract_t\">64,65</a>]. The addition of a third-generation cephalosporin to the empiric treatment of early-onset sepsis may be warranted, but only among severely ill neonates, particularly those in whom a lumbar puncture has not been performed to exclude meningitis. The empiric treatment of suspected late-onset disease is strongly influenced by the clinical setting <span class=\"nowrap\">(hospital-acquired/central-line-associated,</span> or community-acquired disease) and by local bacterial resistance patterns. Empiric therapy for early- and late-onset neonatal sepsis is discussed in greater detail separately. (See <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H5\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Early-onset sepsis'</a> and <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H6\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Late-onset sepsis'</a>.)</p><p><a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin</a> or <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a> should be added to the regimen of infants receiving empiric <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> until GBS meningitis has been excluded [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/54\" class=\"abstract_t\">54</a>]. In vitro, vancomycin is inhibitory rather than bactericidal against GBS, and if the inoculum of GBS in the cerebrospinal fluid (CSF) is high, the CSF concentration of vancomycin will not exceed the mean inhibitory concentration [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H4\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Empiric therapy'</a>.)</p><p>Empiric antibiotic therapy is continued until the causative organism is identified and blood <span class=\"nowrap\">and/or</span> CSF culture is sterile.</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h3\">Definitive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once GBS is identified as the sole causative organism and the patient has improved clinically, we recommend that antimicrobial therapy be changed to <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a> alone (<a href=\"image.htm?imageKey=ID%2F66906\" class=\"graphic graphic_table graphicRef66906 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>]. For infants with GBS meningitis, we suggest repeat lumbar puncture at 24 to 48 hours of therapy to document sterilization of CSF before changing antimicrobial therapy. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H17\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Repeat lumbar puncture'</a>.)</p><p>GBS continues to be susceptible to <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a>, <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, extended-spectrum penicillins, first- and second-generation cephalosporins, and less so to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, but penicillin G is the most narrow-spectrum and active agent in vitro [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,66-69\" class=\"abstract_t\">13,66-69</a>]. Approximately 30 percent of GBS isolates are resistant to <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a> and 20 percent to <a href=\"topic.htm?path=clindamycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clindamycin</a>, rates that appear to be increasing [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,66,70-72\" class=\"abstract_t\">13,66,70-72</a>]. Although most isolates show in vitro resistance to <a href=\"topic.htm?path=gentamicin-pediatric-drug-information\" class=\"drug drug_pediatric\">gentamicin</a>, gentamicin provides synergy with penicillin or ampicillin during initial therapy at achievable serum levels [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/67\" class=\"abstract_t\">67</a>].</p><p>Additional aspects of the management related to the source of infection are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In neonates with meningitis, neuroimaging studies may be warranted. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone and joint infections may require surgical drainage in addition to antimicrobial therapy. (See <a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-management#H630070730\" class=\"medical medical_review\">&quot;Hematogenous osteomyelitis in children: Management&quot;, section on 'Indications for surgery'</a> and <a href=\"topic.htm?path=bacterial-arthritis-treatment-and-outcome-in-infants-and-children#H7\" class=\"medical medical_review\">&quot;Bacterial arthritis: Treatment and outcome in infants and children&quot;, section on 'Drainage'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In neonates with urinary tract infection, radiographic evaluation of the kidneys and urinary tract may be warranted. (See <a href=\"topic.htm?path=urinary-tract-infections-in-neonates#H535026976\" class=\"medical medical_review\">&quot;Urinary tract infections in neonates&quot;, section on 'Radiographic evaluation'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H30\"><span class=\"h3\">Duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of therapy should be 10 days for sepsis without a focus, 14 to 21 days for meningitis, 14 to 21 days for septic arthritis, and 21 to 28 days for osteomyelitis (<a href=\"image.htm?imageKey=ID%2F66906\" class=\"graphic graphic_table graphicRef66906 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>]. Neonates with urinary tract infection are treated in the same manner as infants with bacteremia.</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">RECURRENT INFECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrent GBS infections are infrequent, occurring in 1 to 6 percent of cases [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3,27,57,73\" class=\"abstract_t\">3,27,57,73</a>]. Vulnerability to recurrent infection probably is caused by a combination of host and pathogen factors. Infants usually fail to have a specific antibody response after infection with GBS, and GBS can be isolated from mucosal surfaces of infants even after parenteral antibiotic treatment for invasive disease [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. Despite these potential contributory factors, the available evidence does <strong>not</strong> support prolonged antibiotic treatment (beyond the clinically indicated duration), prophylactic antibiotics, or intravenous immunoglobulin preparations as strategies to prevent recurrent infection.</p><p>Recurrent infections have most commonly been associated with prematurity. Cases of recurrent neonatal GBS infection related to infected breast milk have been reported [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/74-78\" class=\"abstract_t\">74-78</a>]. In each case report, it is unclear whether breast milk caused the recurrent infection or if exposure to the infected infant caused maternal GBS breast duct colonization.</p><p>Evaluation for extremely rare entities such as improperly treated endocarditis or brain abscess as a potential cause for recurrent GBS infection is generally not indicated [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Recurrent GBS infections usually represent persistent mucosal colonization, but occasionally reinfection occurs. This is illustrated by two studies in which GBS isolates from infants with recurrent infection were analyzed with serotyping and pulsed-field gel electrophoresis [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/73,79\" class=\"abstract_t\">73,79</a>]. Paired isolates from 13 of 15 patients were serotypically and genetically identical; two infants had infections with newly acquired, genetically distinct strains of GBS.</p><p><strong>Treatment</strong> &ndash; When treating recurrent GBS infection, susceptibility testing of the GBS isolate to penicillin is recommended. All GBS isolates to date are susceptible in vitro to penicillin. Treatment for recurrent infection is suggested to be continued for one week longer than the usual course, but there are few data to support this recommendation [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/80\" class=\"abstract_t\">80</a>]. (See <a href=\"#H30\" class=\"local\">'Duration'</a> above.)</p><p><a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifampin</a>, which eliminates colonization in other infections, such as meningococcal disease, does not reliably eradicate mucous membrane colonization with GBS, and it is not recommended for routine use [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/81\" class=\"abstract_t\">81</a>].</p><p class=\"headingAnchor\" id=\"H34\"><span class=\"h1\">PREVENTION</span></p><p class=\"headingAnchor\" id=\"H35\"><span class=\"h2\">Neonatal infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>With the recognition that maternal colonization is the single most important risk factor for early-onset GBS infection, a number of strategies are recommended to prevent GBS disease in the infant [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/82\" class=\"abstract_t\">82</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Screening pregnant women for GBS colonization and intrapartum antibiotic prophylaxis (IAP) during labor for those colonized</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of all women during labor who have specific risk factors for early-onset GBS infection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vaccination of all women when GBS vaccines become available</p><p/><p>Screening programs, IAP, and vaccination to prevent GBS disease are discussed separately. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a> and <a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">&quot;Vaccines for the prevention of group B streptococcal disease&quot;</a>.)</p><p>Maternal IAP does not decrease the risk of late-onset GBS disease. There are no effective strategies to prevent late-onset GBS infection.</p><p class=\"headingAnchor\" id=\"H36\"><span class=\"h2\">Health care-associated infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine hand hygiene by health care professionals is the best way to prevent health care-associated spread of GBS infection. Infants admitted to the hospital with suspected GBS infection should be placed on standard isolation precautions [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H2\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Standard precautions'</a>.)</p><p>In the rare event of a nursery outbreak of GBS infection, cohorting ill and colonized infants and the use of contact precautions are recommended [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H954996324\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Contact precautions'</a>.)</p><p class=\"headingAnchor\" id=\"H37\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Case fatality rates for early-onset GBS disease range from 2 to 3 percent for term infants without meningitis to 20 percent for preterm infants. Case fatality rates for late-onset GBS disease range from to 1 to 2 percent for term infants to 5 to 6 percent for preterm infants [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13,27\" class=\"abstract_t\">13,27</a>]. Clinical features associated with increased risk of mortality in early-onset GBS infection include birth weight &lt;2500 g, absolute neutrophil count &lt;1500 <span class=\"nowrap\">cells/microL,</span> hypotension, apnea, and pleural effusion [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/83\" class=\"abstract_t\">83</a>].</p><p>There is little information about the long-term outcome of survivors of GBS bacteremia or sepsis without a focus [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/27\" class=\"abstract_t\">27</a>]. Most information regarding outcome in survivors of GBS meningitis is based on reports of infants cared for before the late 1980s [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/50,84-89\" class=\"abstract_t\">50,84-89</a>]. In those reports, one-fourth to one-half of survivors had permanent neurologic sequelae (eg, profound intellectual disability, spastic quadriplegia, cortical blindness, deafness, uncontrolled seizures, hypothalamic dysfunction).</p><p>Modern outcomes may not be much improved. A study of 53 term and near-term (36 weeks' gestation) infants with neonatal GBS meningitis occurring from 1998 to 2006 revealed that despite advances in intensive care, 26 percent of the study infants died or had neurologic impairment at hospital discharge [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/90\" class=\"abstract_t\">90</a>]. In multivariate analysis, the single predictor of death or a poor neurologic outcome was seizures as a presenting feature of illness. Among 43 survivors of GBS meningitis occurring from 1998 to 2006 who underwent follow-up examination at age 3 through 12 years, 24 (56 percent) demonstrated age-appropriate development, 8 (19 percent) had severe impairment (eg, cognitive skills &gt;2 standard deviations [SD] below the mean in at least one domain, severe neurologic or functional impairment), and 11 (25 percent) had mild-to-moderate impairment (eg, cognitive skills within 1 to 2 SD below the mean in any domain, academic underachievement, evidence of mild neurologic or functional impairment) [<a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/91\" class=\"abstract_t\">91</a>]. (See <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H19\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Outcome'</a> and <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-neurologic-complications\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Neurologic complications&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2677134584\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Sepsis in neonates&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Group B streptococcal infection in pregnant women and neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=group-b-streptococcal-disease-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Group B streptococcal disease (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=group-b-streptococcus-and-pregnancy-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Group B streptococcus and pregnancy (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H39\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Group B <em>Streptococcus</em> (GBS or <em>Streptococcus agalactiae</em>) infection in neonates and young infants is classified by age at onset into early-onset (&lt;7 days of age), late-onset (7 to 89 days), and late, late-onset infection (&ge;90 days). (See <a href=\"#H2\" class=\"local\">'Terminology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early-onset GBS infection in neonates is acquired in utero or during passage through the vagina. Late-onset GBS infection also can be acquired vertically at birth and horizontally in household and community settings. (See <a href=\"#H6\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Universal antenatal screening of pregnant women for GBS colonization at 35 to 37 weeks' gestation and widespread use of intrapartum chemoprophylaxis have resulted in a decline in early-onset GBS disease in the United States but have had not changed the rate of late-onset GBS disease (<a href=\"image.htm?imageKey=PEDS%2F54049\" class=\"graphic graphic_figure graphicRef54049 \">figure 1</a>). (See <a href=\"#H8\" class=\"local\">'Incidence'</a> above and <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors for early-onset GBS disease include delivery at &lt;37 weeks' gestation, premature rupture of membranes, rupture of membranes for &ge;18 hours before delivery, chorioamnionitis, maternal temperature &ge;38&deg;C during labor, maternal GBS bacteriuria during the current pregnancy, prior delivery of an infant with GBS disease, and heavy maternal colonization. (See <a href=\"#H9\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical manifestations of GBS disease vary somewhat according to the timing of onset (see <a href=\"#H11\" class=\"local\">'Clinical manifestations'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Early-onset</strong> &ndash; Early-onset GBS infection most commonly manifests as generalized sepsis, and less commonly as pneumonia or meningitis. Clinical signs usually are apparent in the first 24 hours after birth. Signs of sepsis are nonspecific and include irritability, lethargy, respiratory symptoms (eg, tachypnea, grunting, hypoxia), temperature instability, poor perfusion, and hypotension (<a href=\"image.htm?imageKey=PEDS%2F72985\" class=\"graphic graphic_table graphicRef72985 \">table 1</a>). (See <a href=\"#H12\" class=\"local\">'Early-onset disease'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Late-onset</strong> &ndash; Late-onset GBS disease most often presents as bacteremia without a focus or meningitis. Less common but well-described late-onset GBS focal infections include septic arthritis, osteomyelitis, and cellulitis-adenitis. (See <a href=\"#H16\" class=\"local\">'Late-onset disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation for suspected GBS infection includes (see <a href=\"#H21\" class=\"local\">'Evaluation'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Complete blood count with differential</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blood culture</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Chest radiograph (if respiratory signs are present)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Lumbar puncture for cerebrospinal fluid cell count, protein and glucose concentration, Gram stain and culture</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Urine culture (if the infant is &gt;6 days of age)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If osteoarticular infection is suspected, additional evaluation may include radiographs of affected extremities, magnetic resonance imaging, and bone biopsy or joint aspiration (see <a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-evaluation-and-diagnosis#H18\" class=\"medical medical_review\">&quot;Hematogenous osteomyelitis in children: Evaluation and diagnosis&quot;, section on 'Diagnostic approach'</a> and <a href=\"topic.htm?path=bacterial-arthritis-clinical-features-and-diagnosis-in-infants-and-children#H8\" class=\"medical medical_review\">&quot;Bacterial arthritis: Clinical features and diagnosis in infants and children&quot;, section on 'Evaluation'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Isolation of GBS from a normally sterile body site confirms the diagnosis of GBS infection. (See <a href=\"#H24\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimicrobial therapy and supportive care combined with drainage of purulent collections as necessary are the cornerstones of treatment of GBS disease in neonates and young infants. (See <a href=\"#H25\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial empiric antibiotic therapy for the neonate or young infant with suspected GBS disease should include broad coverage for the most likely pathogens in this age group (GBS and other streptococci, gram-negative enteric organisms, and, rarely, <em>Listeria monocytogenes</em>). Appropriate regimens vary depending upon the focus of infection and whether the infection is early- or late-onset (<a href=\"image.htm?imageKey=ID%2F66906\" class=\"graphic graphic_table graphicRef66906 \">table 2</a>). Local antibiotic resistance patterns should also be considered. (See <a href=\"#H28\" class=\"local\">'Empiric therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once GBS is identified as the sole causative organism and the patient has improved clinically, we suggest changing the antimicrobial therapy to <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">penicillin G</a> alone (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). For infants with GBS meningitis, a repeat lumbar puncture should be performed at 24 to 48 hours of therapy to document sterilization of CSF before changing antimicrobial therapy. (See <a href=\"#H29\" class=\"local\">'Definitive therapy'</a> above and <a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome#H17\" class=\"medical medical_review\">&quot;Bacterial meningitis in the neonate: Treatment and outcome&quot;, section on 'Repeat lumbar puncture'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mortality rates in early-onset GBS disease range from 2 to 3 percent in term infants to 20 percent in preterm infants; for late-onset GBS disease, mortality rates range from 1 to 2 percent in term infants to 5 to 6 percent in preterm infants. Morbidity from GBS meningitis is substantial. (See <a href=\"#H37\" class=\"local\">'Outcome'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/1\" class=\"nounderline abstract_t\">Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr 1973; 83:919.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/2\" class=\"nounderline abstract_t\">Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/4\" class=\"nounderline abstract_t\">Eichenwald EC. Perinatally transmitted neonatal bacterial infections. Infect Dis Clin North Am 1997; 11:223.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/5\" class=\"nounderline abstract_t\">Hussain SM, Luedtke GS, Baker CJ, et al. Invasive group B streptococcal disease in children beyond early infancy. Pediatr Infect Dis J 1995; 14:278.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/6\" class=\"nounderline abstract_t\">Guilbert J, Levy C, Cohen R, et al. Late and ultra late onset Streptococcus B meningitis: clinical and bacteriological data over 6 years in France. Acta Paediatr 2010; 99:47.</a></li><li class=\"breakAll\">Madoff LC, Kasper DL. Group B streptococcal infection. In: Obstetric and Perinatal Infections, Charles D (Ed), Mosby Year Book, Boston 1993. p.210.</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/8\" class=\"nounderline abstract_t\">Ancona RJ, Ferrieri P, Williams PP. Maternal factors that enhance the acquisition of group-B streptococci by newborn infants. J Med Microbiol 1980; 13:273.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/9\" class=\"nounderline abstract_t\">Pass MA, Gray BM, Khare S, Dillon HC Jr. Prospective studies of group B streptococcal infections in infants. J Pediatr 1979; 95:437.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/10\" class=\"nounderline abstract_t\">Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 1992; 41:25.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/11\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Early-onset and late-onset neonatal group B streptococcal disease--United States, 1996-2004. MMWR Morb Mortal Wkly Rep 2005; 54:1205.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/12\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Perinatal group B streptococcal disease after universal screening recommendations--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 2007; 56:701.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/13\" class=\"nounderline abstract_t\">Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention, Active Bacterial Core Surveillance (ABCs) report. Emerging infections program network. Group B Streptococcus, 2015. Available at https://www.cdc.gov/abcs/reports-findings/survreports/gbs15.pdf (Accessed on March 08, 2016).</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/15\" class=\"nounderline abstract_t\">Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45:1.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/16\" class=\"nounderline abstract_t\">Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/17\" class=\"nounderline abstract_t\">Eberly MD, Rajnik M. The effect of universal maternal screening on the incidence of neonatal early-onset group B streptococcal disease. Clin Pediatr (Phila) 2009; 48:369.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/18\" class=\"nounderline abstract_t\">Pulver LS, Hopfenbeck MM, Young PC, et al. Continued early onset group B streptococcal infections in the era of intrapartum prophylaxis. J Perinatol 2009; 29:20.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/19\" class=\"nounderline abstract_t\">Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009; 360:2626.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/20\" class=\"nounderline abstract_t\">Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005; 115:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/21\" class=\"nounderline abstract_t\">Puopolo KM, Madoff LC. Type IV neonatal early-onset group B streptococcal disease in a United States hospital. J Clin Microbiol 2007; 45:1360.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/22\" class=\"nounderline abstract_t\">Stoll BJ, Hansen NI, S&aacute;nchez PJ, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011; 127:817.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/23\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Trends in perinatal group B streptococcal disease - United States, 2000-2006. MMWR Morb Mortal Wkly Rep 2009; 58:109.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2010. www.cdc.gov/abcs/reports-findings/survreports/gbs10.html (Accessed on May 11, 2012).</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/25\" class=\"nounderline abstract_t\">Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008; 27:1057.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). ABCs Report: Group B Streptococcus, 2012. http://www.cdc.gov/abcs/reports-findings/survreports/gbs12.html (Accessed on June 18, 2014).</li><li class=\"breakAll\">Edwards MS, Nizet V, Baker CJ. Group B streptococcal infections. In: Remington and Klein's infectious diseases of the fetus and newborn infant, 8th Ed, Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO (Eds), Saunders, Philadelphia 2016. p.411.</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/28\" class=\"nounderline abstract_t\">Anthony BF, Okada DM, Hobel CJ. Epidemiology of the group B streptococcus: maternal and nosocomial sources for infant acquisitions. J Pediatr 1979; 95:431.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/29\" class=\"nounderline abstract_t\">Easmon CS, Hastings MJ, Clare AJ, et al. Nosocomial transmission of group B streptococci. Br Med J (Clin Res Ed) 1981; 283:459.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/30\" class=\"nounderline abstract_t\">Paredes A, Wong P, Mason EO Jr, et al. Nosocomial transmission of group B Streptococci in a newborn nursery. Pediatrics 1977; 59:679.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/31\" class=\"nounderline abstract_t\">Baker CJ. Group B streptococcal infections. Clin Perinatol 1997; 24:59.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/32\" class=\"nounderline abstract_t\">Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012; 129:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/33\" class=\"nounderline abstract_t\">Puopolo KM, Draper D, Wi S, et al. Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics 2011; 128:e1155.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/34\" class=\"nounderline abstract_t\">Edwards MS, Jackson CV, Baker CJ. Increased risk of group B streptococcal disease in twins. JAMA 1981; 245:2044.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/35\" class=\"nounderline abstract_t\">Pass MA, Khare S, Dillon HC Jr. Twin pregnancies: incidence of group B streptococcal colonization and disease. J Pediatr 1980; 97:635.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/36\" class=\"nounderline abstract_t\">Schuchat A, Oxtoby M, Cochi S, et al. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. J Infect Dis 1990; 162:672.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/37\" class=\"nounderline abstract_t\">Schuchat A, Deaver-Robinson K, Plikaytis BD, et al. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. Pediatr Infect Dis J 1994; 13:623.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/38\" class=\"nounderline abstract_t\">Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/39\" class=\"nounderline abstract_t\">Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004; 190:928.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/40\" class=\"nounderline abstract_t\">Adderson EE, Takahashi S, Bohnsack JF. Bacterial genetics and human immunity to group B streptococci. Mol Genet Metab 2000; 71:451.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/41\" class=\"nounderline abstract_t\">Gotoff SP, Odell C, Papierniak CK, et al. Human IgG antibody to group b Streptococcus type III: comparison of protective levels in a murine model with levels in infected human neonates. J Infect Dis 1986; 153:511.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/42\" class=\"nounderline abstract_t\">Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 2014; 209:781.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/43\" class=\"nounderline abstract_t\">Slotved HC, Kong F, Lambertsen L, et al. Serotype IX, a Proposed New Streptococcus agalactiae Serotype. J Clin Microbiol 2007; 45:2929.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/44\" class=\"nounderline abstract_t\">Fluegge K, Supper S, Siedler A, Berner R. Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2 years in Germany. Clin Infect Dis 2005; 40:760.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/45\" class=\"nounderline abstract_t\">Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants &gt;/=2000 grams at birth: A population-based study. Pediatrics 2000; 106:256.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/46\" class=\"nounderline abstract_t\">Bromberger P, Lawrence JM, Braun D, et al. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. Pediatrics 2000; 106:244.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/47\" class=\"nounderline abstract_t\">Baker CJ. Early onset group B streptococcal disease. J Pediatr 1978; 93:124.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/48\" class=\"nounderline abstract_t\">Long WA, Lawson EE, Harned HS Jr, Kraybill EN. Pleural effusion in the first days of life: a prospective study. Am J Perinatol 1984; 1:190.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/49\" class=\"nounderline abstract_t\">Weller MH, Katzenstein AA. Radiological findings in group B streptococcal Sepsis. Radiology 1976; 118:385.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/50\" class=\"nounderline abstract_t\">Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr 1973; 82:724.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/51\" class=\"nounderline abstract_t\">Weisman LE, Stoll BJ, Cruess DF, et al. Early-onset group B streptococcal sepsis: a current assessment. J Pediatr 1992; 121:428.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/52\" class=\"nounderline abstract_t\">Pe&ntilde;a BM, Harper MB, Fleisher GR. Occult bacteremia with group B streptococci in an outpatient setting. Pediatrics 1998; 102:67.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/53\" class=\"nounderline abstract_t\">Berardi A, Rossi C, Lugli L, et al. Group B streptococcus late-onset disease: 2003-2010. Pediatrics 2013; 131:e361.</a></li><li class=\"breakAll\">Pannaraj PS, Baker CJ. Group B streptococcal infections. In: Feigin and Cherry&rsquo;s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.1153.</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/55\" class=\"nounderline abstract_t\">Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J Pediatr 1973; 82:707.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/56\" class=\"nounderline abstract_t\">Edwards MS, Baker CJ, Wagner ML, et al. An etiologic shift in infantile osteomyelitis: the emergence of the group B streptococcus. J Pediatr 1978; 93:578.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/57\" class=\"nounderline abstract_t\">Yagupsky P, Menegus MA, Powell KR. The changing spectrum of group B streptococcal disease in infants: an eleven-year experience in a tertiary care hospital. Pediatr Infect Dis J 1991; 10:801.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/58\" class=\"nounderline abstract_t\">Baker CJ. Group B streptococcal cellulitis-adenitis in infants. Am J Dis Child 1982; 136:631.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/59\" class=\"nounderline abstract_t\">Albanyan EA, Baker CJ. Is lumbar puncture necessary to exclude meningitis in neonates and young infants: lessons from the group B streptococcus cellulitis- adenitis syndrome. Pediatrics 1998; 102:985.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/60\" class=\"nounderline abstract_t\">Di John D, Krasinski K, Lawrence R, et al. Very late onset of group B streptococcal disease in infants infected with the human immunodeficiency virus. Pediatr Infect Dis J 1990; 9:925.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/61\" class=\"nounderline abstract_t\">De Witt CC, Ascher DP, Winkelstein J. Group B streptococcal disease in a child beyond early infancy with a deficiency of the second component of complement (C2). Pediatr Infect Dis J 1999; 18:77.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/62\" class=\"nounderline abstract_t\">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/63\" class=\"nounderline abstract_t\">Kuzniewicz MW, Puopolo KM, Fischer A, et al. A Quantitative, Risk-Based Approach to the Management of Neonatal Early-Onset Sepsis. JAMA Pediatr 2017; 171:365.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/64\" class=\"nounderline abstract_t\">Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003; 3:201.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/65\" class=\"nounderline abstract_t\">Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics 2010; 125:e1031.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/66\" class=\"nounderline abstract_t\">Biedenbach DJ, Stephen JM, Jones RN. Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program--North America, 2001. Diagn Microbiol Infect Dis 2003; 46:291.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/67\" class=\"nounderline abstract_t\">Schauf V, Deveikis A, Riff L, Serota A. Antibiotic-killing kinetics of group B streptococci. J Pediatr 1976; 89:194.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/68\" class=\"nounderline abstract_t\">Murdoch DR, Reller LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob Agents Chemother 2001; 45:3623.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/69\" class=\"nounderline abstract_t\">Lin FY, Azimi PH, Weisman LE, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis 2000; 31:76.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/70\" class=\"nounderline abstract_t\">Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol 1998; 92:258.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/71\" class=\"nounderline abstract_t\">Manning SD, Foxman B, Pierson CL, et al. Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet Gynecol 2003; 101:74.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/72\" class=\"nounderline abstract_t\">de Azavedo JC, McGavin M, Duncan C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother 2001; 45:3504.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/73\" class=\"nounderline abstract_t\">Green PA, Singh KV, Murray BE, Baker CJ. Recurrent group B streptococcal infections in infants: clinical and microbiologic aspects. J Pediatr 1994; 125:931.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/74\" class=\"nounderline abstract_t\">Wang LY, Chen CT, Liu WH, Wang YH. Recurrent neonatal group B streptococcal disease associated with infected breast milk. Clin Pediatr (Phila) 2007; 46:547.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/75\" class=\"nounderline abstract_t\">Kotiw M, Zhang GW, Daggard G, et al. Late-onset and recurrent neonatal Group B streptococcal disease associated with breast-milk transmission. Pediatr Dev Pathol 2003; 6:251.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/76\" class=\"nounderline abstract_t\">Jones SM, Steele RW. Recurrent group B streptococcal bacteremia. Clin Pediatr (Phila) 2012; 51:884.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/77\" class=\"nounderline abstract_t\">Soukka H, Rantakokko-Jalava K, V&auml;h&auml;kuopus S, Ruuskanen O. Three distinct episodes of GBS septicemia in a healthy newborn during the first month of life. Eur J Pediatr 2010; 169:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/78\" class=\"nounderline abstract_t\">Gagneur A, H&eacute;ry-Arnaud G, Croly-Labourdette S, et al. Infected breast milk associated with late-onset and recurrent group B streptococcal infection in neonatal twins: a genetic analysis. Eur J Pediatr 2009; 168:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/79\" class=\"nounderline abstract_t\">Moylett EH, Fernandez M, Rench MA, et al. A 5-year review of recurrent group B streptococcal disease: lessons from twin infants. Clin Infect Dis 2000; 30:282.</a></li><li class=\"breakAll\">Edwards MS, Baker CJ. Streptococcus agalactiae (Group B streptococcus. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Edinburgh 2012. p.707.</li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/81\" class=\"nounderline abstract_t\">Fernandez M, Rench MA, Albanyan EA, et al. Failure of rifampin to eradicate group B streptococcal colonization in infants. Pediatr Infect Dis J 2001; 20:371.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/82\" class=\"nounderline abstract_t\">Schuchat A. Group B streptococcus. Lancet 1999; 353:51.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/83\" class=\"nounderline abstract_t\">Payne NR, Burke BA, Day DL, et al. Correlation of clinical and pathologic findings in early onset neonatal group B streptococcal infection with disease severity and prediction of outcome. Pediatr Infect Dis J 1988; 7:836.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/84\" class=\"nounderline abstract_t\">Edwards MS, Rench MA, Haffar AA, et al. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr 1985; 106:717.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/85\" class=\"nounderline abstract_t\">Chin KC, Fitzhardinge PM. Sequelae of early-onset group B hemolytic streptococcal neonatal meningitis. J Pediatr 1985; 106:819.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/86\" class=\"nounderline abstract_t\">Haslam RH, Allen JR, Dorsen MM, et al. The sequelae of group B beta-hemolytic streptococcal meningitis in early infancy. Am J Dis Child 1977; 131:845.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/87\" class=\"nounderline abstract_t\">McReynolds EW, Roy S 3rd. Case report. Diabetes insipidus secondary to group B beta streptococcal meningitis. J Tenn Med Assoc 1974; 67:117.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/88\" class=\"nounderline abstract_t\">Wald ER, Bergman I, Taylor HG, et al. Long-term outcome of group B streptococcal meningitis. Pediatrics 1986; 77:217.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/89\" class=\"nounderline abstract_t\">Barton LL, Feigin RD, Lins R. Group B beta hemolytic streptococcal meningitis in infants. J Pediatr 1973; 82:719.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/90\" class=\"nounderline abstract_t\">Levent F, Baker CJ, Rench MA, Edwards MS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J 2010; 29:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/group-b-streptococcal-infection-in-neonates-and-young-infants/abstract/91\" class=\"nounderline abstract_t\">Libster R, Edwards KM, Levent F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012; 130:e8.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5961 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H39\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">TERMINOLOGY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">PATHOGENESIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">EPIDEMIOLOGY</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Incidence</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Risk factors</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Serotype distribution</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Early-onset disease</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Sepsis</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Pneumonia</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Meningitis</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">Late-onset disease</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">- Bacteremia</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Meningitis</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Other focal infection</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">Late, late-onset disease</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">EVALUATION</a><ul><li><a href=\"#H593758555\" id=\"outline-link-H593758555\">Clinical suspicion</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Tests to perform in the index patient</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Evaluation of a twin sibling</a></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">DIAGNOSIS</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">MANAGEMENT</a><ul><li><a href=\"#H26\" id=\"outline-link-H26\">Supportive care</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">Antimicrobial therapy</a><ul><li><a href=\"#H28\" id=\"outline-link-H28\">- Empiric therapy</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">- Definitive therapy</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">- Duration</a></li></ul></li></ul></li><li><a href=\"#H32\" id=\"outline-link-H32\">RECURRENT INFECTION</a></li><li><a href=\"#H34\" id=\"outline-link-H34\">PREVENTION</a><ul><li><a href=\"#H35\" id=\"outline-link-H35\">Neonatal infection</a></li><li><a href=\"#H36\" id=\"outline-link-H36\">Health care-associated infection</a></li></ul></li><li><a href=\"#H37\" id=\"outline-link-H37\">OUTCOME</a></li><li><a href=\"#H2677134584\" id=\"outline-link-H2677134584\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H38\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H39\" id=\"outline-link-H39\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/5961|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/56780\" class=\"graphic graphic_algorithm\">- Secondary prevention early-onset GBS disease among newborns</a></li></ul></li><li><div id=\"PEDS/5961|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/54049\" class=\"graphic graphic_figure\">- Incidence of invasive group B streptococcal disease</a></li></ul></li><li><div id=\"PEDS/5961|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/72985\" class=\"graphic graphic_table\">- Findings neonatal sepsis</a></li><li><a href=\"image.htm?imageKey=ID/66906\" class=\"graphic graphic_table\">- Neonatal GBS infection rx</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anemia-of-prematurity\" class=\"medical medical_review\">Anemia of prematurity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-arthritis-clinical-features-and-diagnosis-in-infants-and-children\" class=\"medical medical_review\">Bacterial arthritis: Clinical features and diagnosis in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-arthritis-treatment-and-outcome-in-infants-and-children\" class=\"medical medical_review\">Bacterial arthritis: Treatment and outcome in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-children-older-than-one-month-clinical-features-and-diagnosis\" class=\"medical medical_review\">Bacterial meningitis in children older than one month: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-clinical-features-and-diagnosis\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-neurologic-complications\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Neurologic complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-the-neonate-treatment-and-outcome\" class=\"medical medical_review\">Bacterial meningitis in the neonate: Treatment and outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-bacterial-sepsis-in-the-preterm-infant-less-than34-weeks-gestation\" class=\"medical medical_review\">Clinical features and diagnosis of bacterial sepsis in the preterm infant (&lt;34 weeks gestation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-clinical-manifestations-evaluation-and-management-of-neonatal-shock\" class=\"medical medical_review\">Etiology, clinical manifestations, evaluation, and management of neonatal shock</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=febrile-infant-younger-than-90-days-of-age-outpatient-evaluation\" class=\"medical medical_review\">Febrile infant (younger than 90 days of age): Outpatient evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">Fluid and electrolyte therapy in newborns</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcus-virulence-factors-and-pathogenic-mechanisms\" class=\"medical medical_review\">Group B streptococcus: Virulence factors and pathogenic mechanisms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-evaluation-and-diagnosis\" class=\"medical medical_review\">Hematogenous osteomyelitis in children: Evaluation and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-management\" class=\"medical medical_review\">Hematogenous osteomyelitis in children: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Management and outcome of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-the-infant-whose-mother-has-received-group-b-streptococcal-chemoprophylaxis\" class=\"medical medical_review\">Management of the infant whose mother has received group B streptococcal chemoprophylaxis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">Mechanical ventilation in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">Neonatal group B streptococcal disease: Prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-pneumonia\" class=\"medical medical_review\">Neonatal pneumonia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-clinical-manifestations-and-diagnosis-of-respiratory-distress-syndrome-in-the-newborn\" class=\"medical medical_review\">Pathophysiology, clinical manifestations, and diagnosis of respiratory distress syndrome in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcal-disease-the-basics\" class=\"medical medical_basics\">Patient education: Group B streptococcal disease (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=group-b-streptococcus-and-pregnancy-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Group B streptococcus and pregnancy (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=persistent-pulmonary-hypertension-of-the-newborn\" class=\"medical medical_review\">Persistent pulmonary hypertension of the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-respiratory-distress-syndrome-in-preterm-infants\" class=\"medical medical_review\">Prevention and treatment of respiratory distress syndrome in preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=red-blood-cell-transfusions-in-the-newborn\" class=\"medical medical_review\">Red blood cell transfusions in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Group B streptococcal infection in pregnant women and neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-sepsis-in-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Sepsis in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transient-tachypnea-of-the-newborn\" class=\"medical medical_review\">Transient tachypnea of the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-neonatal-seizures\" class=\"medical medical_review\">Treatment of neonatal seizures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=urinary-tract-infections-in-neonates\" class=\"medical medical_review\">Urinary tract infections in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-the-prevention-of-group-b-streptococcal-disease\" class=\"medical medical_review\">Vaccines for the prevention of group B streptococcal disease</a></li></ul></div></div>","javascript":null}